Embed Size (px)
Citation preview
Realizing Possibilities, Together
Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com
CROSS-BORDER LIFESCIENCES DEALS (2013-2015): A Perspective
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com
Dinesh Jain| Michael Rosen
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 2
Table of Contents
Overall Pharma Market TrendsM&AJoint Ventures/Co-DevelopmentLicensingAagami Profile
CROSS BORDER LIFESCIENCES DEALS - US & INDIA (2013-2015)
Note : These are some of the deals which Aagami Market Research Team have sourced from Publicly available data and hence not exhaustive
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 3
• Indian Pharma Market = ~ $22 B; projected to grow to $55 B by 2020 (McKinsey)
• India pharma exports $15.2 B in pharmaceutical products ($4.2B to US)
• 584 FDA –approved pharma manufacturing facilities
• >3,000 pharma companies• Bi-national M&A (2013-2015)*
U.S. pharma spent more than $2.7 B to acquire Indian pharma
Indian pharma spent $180 M to acquire U.S. biotech and >$180 M in FDI
* Counting only deal amounts which were publicly disclosed
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 4
Indian Co. US Co.Deal Size - M Year Remarks
Aurobindo Natrol Inc. $132.5 2014 Nutraceuticals platform for US & ROW
PiramalColdstream Laboratories
$30.65 2015 Injectable market segment
SRFDupont $ 20 .0 2015 Pharma propellant business
Sun Pharma Pharmalucence N/A 2014 Radio- pharmaceuticals and US injectable business
KemwellCirrus N/A 2013 Products with faster time-to-clinic and cost savings for
customers
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 5
US Co. Indian Co. Deal Size - M Year Remarks
Mylan Agila $1,600 2013 Become top-three global player in injectables
Mylan Famy Care $800 2015 Global women's health care
HospiraOrchid Pharma
$200 2014 API supplier for key antibiotics and future API development.
Carlyle Group
Bharat Serum $83 2014 25-30% stake from existing investors.
Amneal Pharma
Epsilon Pharma
$16 2014Expand footprint in India. Includes 200,000 + sf. US FDA certified manufacturing facility.
Quantum solutions
Parexel N/A 2015Create greater scale in service area, and provide comprehensive and efficient solution to global clients.
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 6
Indian Co. US Co. Year Remarks
Ami Organics Photolitec 2015Clinical trials to determine cancer treatments safety and and efficacy.
EmamiHevert-Arzneimittel
2014Launched products via 400 homoeopathy medicine retail outlets across diverse distribution channels via Emami.
Agila Biotech Pfenex Inc 2013Develop, manufacture and commercialize initial pipeline of 6 biosimilar products. AB = 51% equity stakeholder
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 7
Indian Co. US Co. Year Remarks
Ipca Labs
Oncobiologics 2014Development, manufacture and commercialization of biosimilar monoclonal antibodies.
Cipla BioQuiddity 2014Commercial collaboration on OneDose ReadyfusOR™ in anaesthetic applications for post-surgical pain management.
GVK Bio Endo Pharma 2013Novel small molecules. GVK BIO will use discovery expertise and Endo will develop/commercialize product.
Advinus Moffitt Cancer Centre
2013 New oncology therapies.
GVK BioOnconova Therapeutics
2013US JV to move Onconova oncology assets from early discovery to clinical development stage.
Cadila Novavax 2013 Extension to JV in 2009 collaboration to develop novel malaria vaccine in India.
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 8
Indian Co. US Co. Deal Size - M Year Remarks
Lupin US Market $177.5 20142 new US R&D Centres on inhalation and complex formulations research.
Glenmark US Market $100 2014 Greenfield facility for US market.
Cipla Chase Pharma $6.0 2014Alzheimer’s drug development. Part of $21 M investment through syndicate.
Strides Arcolabs
Oncobiologics N/A 2014 Strategic stake.
Indian Co. US Co. Deal Size - M Year Remarks
Laurus Lab Warburg Pincus $92 2014 Create durable businesses of scale with sustainable value.
Ashland Investment in
India$ 10 2014 2 centres of excellence — new pharma in Hyderabad and
existing personal care in Mumbai
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com 9
Indian Co. US Co. Year Remarks
Sun Pharma Merck 2014 Worldwide rights to tildrakizumab. $ 280 M Deal
MedGenome Natera 2015 Exclusive license to develop Natera's Panorama.
Strides Arcolabs
Gilead 2015 Non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF); license extends to 112 countries
Natco India Gilead 2015 Generic versions of chronic hepatitis C medicines.
Ranbaxy Epirus 2014 Infliximab (arthritis) with annual sales of $6 billion..
Biocon Cytosorbents Corporation
2014 Distribute CytoSorb® for critical care applications in ICU and cardiac surgery applications for India and select emerging countries.
Indian Co. US Co. Year Remarks
Caplin Point Fresenius Kabi
2015 Parenteral products; Fresenius Kabi will hold ANDAs and commercialise in USA.
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com10
Aagami, Inc.
Life Sciences consulting firm based in Chicago suburbs offers:
For Global Biotech, Pharmaceutical , Medical Devices and Consumer Health products companies.
Strategic Consulting ServicesTechnology Licensing ServicesBusiness & Market Research Services
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com11
Strategic Consulting Services
In-Licensing/Out-Licensing
Co-Development & Partnerships
Investments to/from US, India, Asia, Latin America
Mergers & Acquisitions
Finding the Right Partners
JV and/or Distributors
CRO/CRAMS providers
Contract Sales/Marketing
Contract Manufacturing
12
Aagami Clients
InternationalPhosphagenics Australia
PeptiSyntha Belgium
DelMar Pharma Canada
Affitech Denmark
Pieris Germany
Merus Holland
Venus Remedies India
Opsona Ireland
Toppan Japan
Otago University New Zealand
Aagami has completed over 100 assignments for more than 50 clients in the last 11+ years.
United States
Advangene IL
Loyola Univ. Chicago IL
Dow Chemicals MI
ScyFIX MN
OncBioMune LA
Penwest Corp. NY
DesignMedix OR
PLx TX
CreAgri CA
New Heaven Pharma CT
13
Aagami Connectivity in India
We are connected at CXO Level of TOP 100 Lifesciences companies in India including:
Biocon Intas Sun Pharma
Cadila Lupin Themis
Cipla MicroLabs Torrent Pharma
Dr Reddys Piramal USV
Glenmark Reliance Wockhardt
Hetero Drugs Strides Zydus
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com
USA (Head Office)
Aagami, Inc. 2135 City Gate Lane Suite 300
Naperville, IL 60653
P: +1-630-364-1837
INDIA
Aagami
741, Nelson Square
Nagpur – 440013
P: +91-712-258-6678
Dinesh Jain
Email: [email protected]
M: +1 630-853-3520
Godwyn Francis
Email: [email protected]
M: +91-787-501-6957
www.aagami.com14
Realizing Possibilities, Together
